Summary
The use of adjuvant chemotherapy following the primary treatment of breast cancer has led to an increased disease-free survival. The outlook for patients who present with metastatic disease however remains dismal, with little improvement in survival in the last decade. A recent analysis by Bonadonna and his colleagues has demonstrated a strong influence of the dose of drugs administered on relapse-free survival in patients with breast cancer receiving adjuvant therapy and those with metastatic disease. The utilization of cryopreserved autologous bone marrow permits the use of more aggressive therapy without regard to marrow toxicity, the dose-limiting feature of many antineoplastic agents. Some of the questions and potential problems with the use of autologous marrow rescue in solid tumors is discussed. Preliminary data on a protocol to evaluate the role of high-dose cyclophosphamide and total body irradiation with autologous marrow transplantation in patients with metastatic breast carcinoma are presented.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Fischer B, Redmond C, Wolmark N, and participatory NSABP investigators: Breast cancer studies of the NSABP: An editorialized overview.In SE Jones and SE Salmon (eds): Adjuvant Therapy of Cancer III. Grune and Stratton, New York, 1981, pp 359–369.
Bonadonna G, Valagussa P, Rossi A, Tancini G, Brambilla C, Marchini S, Veronesi U: Multimodal therapy with CMF in resectable breast cancer with positive axillary nodes. The Milan Institute experience.In SE Jones and SE Salmon (eds): Adjuvant Therapy of Cancer III. Grune and Stratton, New York, 1981, pp 435–444.
Young RC, Lippman M, De Vita VT, Bull J, Tormey D: Perspectives in the treatment of breast cancer: 1976. Ann Intern Med 86: 784–798, 1977.
Carter SK: Chemotherapy in advanced breast cancer. Int J Radiat Oncol Biol Phys 4: 309–311, 1978.
Stewart PS, Buckner CD, Clift RA, Sanders JE, Storb R, Leonard JM, Thomas ED: Allogeneic marrow grafting for acute leukemia: A follow-up of long-term survivors. Exp Hematol 7: 509–518, 1979.
Thomas ED, Buckner CD, Clift RA, Fefer A, Johnson FL, Neiman PE, Sale GE, Sanders JE, Singer JW, Shulman H, Storb R, Weiden PL: Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med 301: 597–599, 1979.
Bruce WR, Meeker BE, Valeriote FA: Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo. J Natl Cancer Inst 37: 233–245, 1966.
Frei E III, Canellos GP: Dose: A critical factor in cancer chemotherapy. Am J Med 69: 585–594, 1980.
Cohen MH, Creaven PJ, Fossieck BE Jr, Broder LE, Selawry OS, Johnston AV, Williams CL, Minna JD: Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep 61: 349–354, 1977.
Appelbaum FR, Deisseroth AB, Graw RG Jr, Herzig GP, Levine AS, Magrath IT, Pizzo PA, Poplack DG, Ziegler JL: Prolonged complete remission following high dose chemotherapy of Burkitt's lymphoma in relapse. Cancer 41: 1059–1063, 1978.
Appelbaum FR, Fefer A, Cheever MA, Buckner CD, Greenberg PD, Kaplan HG, Storb R, Thomas ED: Treatment of non-Hodgkin's lymphoma with marrow transplantation in identical twins. Blood 58: 509–513, 1981.
Bonadonna G, Valagussa P: Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304: 10–15, 1981.
Buckner CD, Rudolph RH, Fefer A, Clift RA, Epstein RB, Funk DD, Neiman PE, Slichter SJ, Storb R, Thomas ED: High-dose cyclophosphamide therapy for malignant disease. Toxicity, tumor response, and the effects of stored autologous marrow. Cancer 29: 357–365, 1972.
Schell FC, DiStefano A, Spitzer G, Dicke K, Blumenschein GR: Phase I study of high dose mitomycin-C (HDMM) with autologous bone marrow transplantation (ABMT) in refractory breast carcinoma. Proc Am Assoc Cancer Res 22: 144, 1981 (Abstract).
Buckner CD, Appelbaum FR, Thomas ED: Bone marrow and fetal liver.In AM Karow Jr and DE Pegg (eds): Organ Preservation for Transplantation. Marcel Dekker, New York, 1981, pp. 355–375.
Appelbaum FR, Herzig G, Graw RG, Ziegler JL: Accelerated hemopoietic recovery following the infusion of cryopreserved autologous bone marrow in humans. Exp Hematol 7 (Suppl #5): 297–301, 1979.
McElwain TJ, Hedley DW, Burton G, Clink HM, Gordon MY, Jarman M, Juttner CA, Millar JL, Milsted RAV, Prentice G, Smith IE, Spence D, Woods M: Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan. Br J Cancer 40: 72–80, 1979.
Abrams RA, Glaubiger D, Simon R, Lichter A, Deisseroth AB: Haemopoietic recovery in Ewing's sarcoma after intensive combination therapy and autologous marrow infusion. Lancet 2: 385–389, 1980.
Wurster-Hill DH, Maurer LH: Cytogenetic diagnosis of cancer: Abnormalities of chromosomes and polyploid levels in the bone marrow of patients with small cell anaplastic carcinoma of the lung. J Natl Cancer Inst 61: 1065–1069, 1978.
Pollard EB, Tio F, Meyers JW, Clark G, Coltman CA Jr, Von Hoff DD: Utilization of a human tumor cloning system to monitor for marrow involvement with small cell carcinoma of the lung. Cancer Res 41: 1015–1020, 1981.
Norton L, Simon R: Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 61: 1307–1317, 1977.
Fitzpatrick P, Rider W: Half body radiotherapy. Int J Radiat Oncol Phys 1: 197–207, 1976.
Legha SS, Buzdar AU, Smith TL, Hortobagyi GN, Swenerton KD, Blumenschein GR, Gehan EA, Bodey GP, Freireich EJ: Complete remissions in metastatic breast cancer treated with combination drug therapy. Ann Intern Med 91: 847–852, 1979.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stewart, P.S. Autologous bone marrow transplantation in metastatic breast cancer. Breast Cancer Res Tr 2, 85–92 (1982). https://doi.org/10.1007/BF01805720
Issue Date:
DOI: https://doi.org/10.1007/BF01805720